At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
DT2216drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Patients With Relapsed/Refractory Malignancies
In Brief
A Phase 1 clinical trial evaluating DT2216 for Solid Tumor and Hematologic Malignancy. Completed, enrolled 20 participants across 3 sites.
Detailed Summary
A Phase 1, Open-Label, Dose Escalation, and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Clinical Activity of DT2216, an Antiapoptotic Protein Targeted Degradation Compound, in Subjects with Relapsed or Refractory Malignancies
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Hematologic Malignancy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartAug 2021
Primary CompletionJun 2024
TodayJul 2026
First PostedMay 14, 2021
Enrollment StartAug 25, 2021
Primary CompletionJun 30, 2024
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.1 years ago
Interventions
DT2216drug
DT2216 will be administered by intravenous infusion